Biotech co. hosts career fair at new Pearland facility, aims to hire 200 by end of 2019

Switzerland-based biotech giant Lonza Group Ltd. is moving forward with plans to double its workforce at its recently opened Pearland facility, billed as the largest dedicated cell and gene therapy manufacturing facility in the world. The 300,000-square-foot facility officially opened in April with 170 employees. Ricardo Jimenez, site director at Lonza Houston Inc., told the Houston Business Journal at the time that the space could support more than 400 workers.  Now, the company is holding its…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news

Related Links:

Hereditary angioedema (HAE) is a rare genetic disorder primarily caused by mutations in the SERPING1 gene encoding the C1 inhibitor (C1INH) that leads to plasma deficiency, resulting in recurrent attacks of severe swelling. In the current issue of the JCI, Haslund et al. show that in a subset of patients with type I HAE, mutated C1INH encoded by HAE-causing SERPING1 acts upon wildtype (WT) C1INH in a dominant-negative manner and forms intracellular C1INH aggregates. These aggregates lead to a reduction in the levels of secreted functional C1INH, thereby manifesting in the condition that allows the disease state. Interestin...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Authors: Porter J Abstract Transfusion combined with chelation therapy for severe β thalassemia syndromes (transfusion-dependent thalassemia [TDT]) has been successful in extending life expectancy, decreasing comorbidities and improving quality of life. However, this puts lifelong demands not only on the patients but also on the health care systems that are tasked with delivering long-term treatment and comprehensive support. Prevention programs and curative approaches are therefore an important part of overall strategy. Curative treatments alter the dynamic of a patient's health care costs, from financial com...
Source: Hematology ASH Education Program - Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research
Conditions:   Non-hodgkin Lymphoma;   Acute Lymphoblastic Leukemia Interventions:   Biological: CD19.CAR-multiVST for Group A;   Biological: CD19.CAR-multiVST for Group B Sponsors:   Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System;   Center for Cell and Gene Therapy, Baylor College of Medicine Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Inherited primary arrhythmia syndromes are genetically determined disorders of cardiac ion channels or ion channel macromolecular complexes usually associated with a higher risk of sudden cardiac death. These conditions have a very broad spectrum of clinical manifestations, ranging from an asymptomatic course to syncope, atrial and ventricular arrhythmias, and conduction disturbances, but may produce sudden infant death syndrome and unexplained sudden cardiac death in apparently healthy individuals. During the last 20 years, the evolving knowledge on the genetic basis of inherited arrhythmia syndromes has dramatically resh...
Source: Cardiology in Review - Category: Cardiology Tags: Review Articles Source Type: research
Conclusion: Our findings demonstrate that this novel nanoplatform for targeted image-guided treatment of tumor and tactfully integrated chemotherapy, photothermal therapy (PTT) and gene therapy might provide an insight for cancer theranostics.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
GDNF-mediated rescue of the nigrostriatal system depends on the degree of degeneration, Published online: 07 December 2018; doi:10.1038/s41434-018-0049-0GDNF-mediated rescue of the nigrostriatal system depends on the degree of degeneration
Source: Gene Therapy - Category: Genetics & Stem Cells Authors: Source Type: research
Fifty years ago, the idea of altering a gene to treat or even cure a disease was considered science fiction. Today, cell and gene therapy are transforming treatment options for some patients and are part of an exciting new era of medicine.
Source: The Catalyst - Category: Pharmaceuticals Tags: Medicines in Development GoBoldly Source Type: news
XyloCor Therapeutics, a Malvern gene therapy company developing new cardiovascular disease treatments, has closed a $17 million series A financing. The equity financing deal was co-led by Sofinnova Ventures in Menlo Park, Calif., and Life Sciences Partners (LSP), which is based in The Netherlands and has a office in Waltham, Mass.  Proceeds from the financing will be used by XyloCor to advance the development of its lead product candidate, XC001, and to "expand the companies business and operational…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Condition:   Ada-Scid Intervention:   Drug: Lentiviral transduced CD34+ cells Sponsor:   Great Ormond Street Hospital for Children NHS Foundation Trust Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
a breakthrough inIf gene therapy lives up to its promise, it reallywill justify the song and dance
Source: FT.com - Drugs and Healthcare - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Gene Therapy | Genetics | Health Management | Switzerland Health